| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |
|
Medicine details |
|
| Medicine name | trametinib (Mekinist®) |
| Formulation | 0.5 mg, 1 mg, 2 mg film-coated tablet |
| Reference number | 1996 |
| Indication | In combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior BRAF inhibitor therapy |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 13/11/2015 |
| NICE guidance | TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |